ROIV
FDA Approves Lisraya, First Oral Drug for Dermatomyositis in Adults
The FDA has cleared Lisraya (brepocitinib) tablets, the first oral therapy specifically indicated for adults with dermatomyositis.
ROIV
Market-moving news on Roivant Sciences (NASDAQ: ROIV): filings, earnings, deals and other events, from REDFILED.